Ellen Q. Wang

953 total citations
17 papers, 403 citations indexed

About

Ellen Q. Wang is a scholar working on Immunology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Ellen Q. Wang has authored 17 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Molecular Biology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Ellen Q. Wang's work include Biosimilars and Bioanalytical Methods (3 papers), Pharmaceutical Economics and Policy (3 papers) and Dermatology and Skin Diseases (2 papers). Ellen Q. Wang is often cited by papers focused on Biosimilars and Bioanalytical Methods (3 papers), Pharmaceutical Economics and Policy (3 papers) and Dermatology and Skin Diseases (2 papers). Ellen Q. Wang collaborates with scholars based in United States and United Kingdom. Ellen Q. Wang's co-authors include Christie M. Ballantyne, Kevin Sweeney, Harold Bays, Joel Neutel, William Duggan, John Vincent, David R. Plowchalk, Bimal Malhotra, Lisy Wang and Martin E. Dowty and has published in prestigious journals such as Cancer Research, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Ellen Q. Wang

17 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen Q. Wang United States 9 141 97 83 55 53 17 403
Eyas Raddad United States 12 101 0.7× 195 2.0× 105 1.3× 52 0.9× 39 0.7× 21 602
Sandesh Chopade United Kingdom 5 76 0.5× 155 1.6× 32 0.4× 24 0.4× 19 0.4× 10 416
Akashi Izumi Japan 11 211 1.5× 226 2.3× 126 1.5× 38 0.7× 18 0.3× 12 550
Ion Agirrezabal United Kingdom 8 21 0.1× 124 1.3× 29 0.3× 26 0.5× 39 0.7× 24 288
Tatsiana Castor Germany 13 82 0.6× 163 1.7× 63 0.8× 69 1.3× 27 0.5× 27 496
Michael Grow United States 14 203 1.4× 153 1.6× 58 0.7× 54 1.0× 42 0.8× 23 726
Federico Bigazzi Italy 12 256 1.8× 105 1.1× 46 0.6× 45 0.8× 27 0.5× 47 462
Anne‐Charlotte de Gouville France 8 120 0.9× 481 5.0× 53 0.6× 21 0.4× 29 0.5× 8 791
Enza Di Leo Italy 13 294 2.1× 160 1.6× 27 0.3× 81 1.5× 33 0.6× 21 642

Countries citing papers authored by Ellen Q. Wang

Since Specialization
Citations

This map shows the geographic impact of Ellen Q. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Q. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Q. Wang more than expected).

Fields of papers citing papers by Ellen Q. Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Q. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Q. Wang. The network helps show where Ellen Q. Wang may publish in the future.

Co-authorship network of co-authors of Ellen Q. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Q. Wang. A scholar is included among the top collaborators of Ellen Q. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Q. Wang. Ellen Q. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Crawford, Jeffrey, Roberto A. Calle, Susie M. Collins, et al.. (2023). A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia. Clinical Cancer Research. 30(3). 489–497. 26 indexed citations
2.
Crawford, Jeffrey, Roberto A. Calle, Susie M. Collins, et al.. (2023). Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy. Cancer Research. 83(8_Supplement). CT108–CT108. 4 indexed citations
3.
Chasman, Daniel I., Craig Hyde, Franco Giulianini, et al.. (2022). Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1. Scientific Reports. 12(1). 4266–4266. 4 indexed citations
4.
Wang, Ellen Q., Vu Le, Sangeeta Raje, et al.. (2021). Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. The Journal of Clinical Pharmacology. 62(4). 505–519. 19 indexed citations
5.
Wang, Ellen Q., Vu Le, Melissa O’Gorman, et al.. (2021). Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. The Journal of Clinical Pharmacology. 61(10). 1311–1323. 32 indexed citations
6.
Wang, Ellen Q., Jack F. Bukowski, Carla Yunis, et al.. (2019). Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies. BioDrugs. 33(5). 571–579. 7 indexed citations
7.
8.
9.
Ballantyne, Christie M., Joel Neutel, William Duggan, et al.. (2015). Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia. The American Journal of Cardiology. 115(9). 1212–1221. 142 indexed citations
10.
Fossa, Anthony A., Todd Wisialowski, Thomas I.F.H. Cremers, et al.. (2012). Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine. Toxicology and Applied Pharmacology. 264(3). 343–350. 6 indexed citations
11.
Malhotra, Bimal, Ahmed El‐Tahtawy, Ellen Q. Wang, et al.. (2012). Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. Journal of Pediatric Urology. 8(4). 336–342. 20 indexed citations
12.
Chang, Cheng, Wonkyung Byon, Yifeng Lu, et al.. (2011). Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans. The AAPS Journal. 13(4). 565–575. 36 indexed citations
13.
Tyner, Jeffrey, Luke B. Fletcher, Ellen Q. Wang, et al.. (2010). MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity. Cancer Research. 70(15). 6233–6237. 58 indexed citations
14.
Soares, Holly, Dane Liston, Karen J. Coffman, et al.. (2009). P1‐259: Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers. Alzheimer s & Dementia. 5(4S_Part_8). 8 indexed citations
15.
Soares, Holly, Travis T. Wager, Anne W. Schmidt, et al.. (2009). P1‐264: H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers. Alzheimer s & Dementia. 5(4S_Part_8). 7 indexed citations
16.
Nicholas, Timothy, Rebecca Evans, Scot Styren, et al.. (2009). P2‐240: PF‐04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non‐clinical species to healthy human volunteers. Alzheimer s & Dementia. 5(4S_Part_11). 15 indexed citations
17.
Wang, Ellen Q. & Ho‐Leung Fung. (2002). Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats. PubMed. 4(4). 80–88. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eyas Raddad Breakdown of academic impact, for papers by Sandesh Chopade Breakdown of academic impact, for papers by Akashi Izumi Breakdown of academic impact, for papers by Ion Agirrezabal Breakdown of academic impact, for papers by Tatsiana Castor Breakdown of academic impact, for papers by Michael Grow Breakdown of academic impact, for papers by Federico Bigazzi Breakdown of academic impact, for papers by Anne‐Charlotte de Gouville Breakdown of academic impact, for papers by Enza Di Leo
Rankless by CCL
2026